The relationship between the acute cerebral metabolic response to citalopram and chronic citalopram treatment outcome

Gwenn Smith, Clifford I. Workman, Elisse Kramer, Carol R. Hermann, Rachel Ginsberg, Yilong Ma, Vijay Dhawan, Thomas Chaly, David Eidelberg

Research output: Contribution to journalArticle

Abstract

Objectives: Given the challenges in the clinical management of geriatric depression, research over the past decade has focused on developing early neurobiological markers of antidepressant treatment response. This study tested the hypothesis that lower baseline glucose metabolism and greater acute cerebral metabolic responses to a single, intravenous (IV) dose of the selective serotonin reuptake inhibitor (SSRI) citalopram would be associated with greater improvement of depressive symptoms after 12 weeks of citalopram treatment in geriatric depression. Methods: Sixteen geriatric depressed patients underwent two scans to measure cerebral glucose metabolism after administration of either a saline placebo or citalopram infusion (40 mg, IV). Then, the patients were treated with the oral citalopram medication for 12 weeks. Results: Greater improvement of depressive symptoms was associated with lower baseline metabolism in anterior cingulate, superior, middle, and inferior frontal gyri (bilaterally), inferior parietal lobule (bilaterally), precuneus (right), insula (left), parahippocampal gyrus (right), caudate (bilaterally), and putamen (left) regions. Greater improvement of depressive symptoms was associated with greater reductions in metabolism after acute citalopram administration in similar brain regions, including additional posterior cortical regions. Conclusions: Lower baseline cerebral metabolism and greater decreases with acute citalopram administration are associated with better antidepressant response to chronic citalopram treatment. These data are consistent with previous studies of total sleep deprivation and suggest that dynamic, early adaptive changes or normalization of cerebral metabolism may represent early neurobiological markers of chronic SSRI treatment response in geriatric depression.

Original languageEnglish (US)
Pages (from-to)53-63
Number of pages11
JournalAmerican Journal of Geriatric Psychiatry
Volume19
Issue number1
DOIs
StatePublished - Jan 2011

Fingerprint

Citalopram
Depression
Geriatrics
Parietal Lobe
Serotonin Uptake Inhibitors
Prefrontal Cortex
Antidepressive Agents
Glucose
Parahippocampal Gyrus
Sleep Deprivation
Putamen
Gyrus Cinguli
Therapeutics
Placebos
Brain
Research

Keywords

  • antidepressant
  • biomarker
  • citalopram
  • Depression
  • geriatric
  • glucose metabolism
  • PET
  • treatment response

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Geriatrics and Gerontology

Cite this

The relationship between the acute cerebral metabolic response to citalopram and chronic citalopram treatment outcome. / Smith, Gwenn; Workman, Clifford I.; Kramer, Elisse; Hermann, Carol R.; Ginsberg, Rachel; Ma, Yilong; Dhawan, Vijay; Chaly, Thomas; Eidelberg, David.

In: American Journal of Geriatric Psychiatry, Vol. 19, No. 1, 01.2011, p. 53-63.

Research output: Contribution to journalArticle

Smith, Gwenn ; Workman, Clifford I. ; Kramer, Elisse ; Hermann, Carol R. ; Ginsberg, Rachel ; Ma, Yilong ; Dhawan, Vijay ; Chaly, Thomas ; Eidelberg, David. / The relationship between the acute cerebral metabolic response to citalopram and chronic citalopram treatment outcome. In: American Journal of Geriatric Psychiatry. 2011 ; Vol. 19, No. 1. pp. 53-63.
@article{a068ac364abe4bd6aa82754d250f1b3c,
title = "The relationship between the acute cerebral metabolic response to citalopram and chronic citalopram treatment outcome",
abstract = "Objectives: Given the challenges in the clinical management of geriatric depression, research over the past decade has focused on developing early neurobiological markers of antidepressant treatment response. This study tested the hypothesis that lower baseline glucose metabolism and greater acute cerebral metabolic responses to a single, intravenous (IV) dose of the selective serotonin reuptake inhibitor (SSRI) citalopram would be associated with greater improvement of depressive symptoms after 12 weeks of citalopram treatment in geriatric depression. Methods: Sixteen geriatric depressed patients underwent two scans to measure cerebral glucose metabolism after administration of either a saline placebo or citalopram infusion (40 mg, IV). Then, the patients were treated with the oral citalopram medication for 12 weeks. Results: Greater improvement of depressive symptoms was associated with lower baseline metabolism in anterior cingulate, superior, middle, and inferior frontal gyri (bilaterally), inferior parietal lobule (bilaterally), precuneus (right), insula (left), parahippocampal gyrus (right), caudate (bilaterally), and putamen (left) regions. Greater improvement of depressive symptoms was associated with greater reductions in metabolism after acute citalopram administration in similar brain regions, including additional posterior cortical regions. Conclusions: Lower baseline cerebral metabolism and greater decreases with acute citalopram administration are associated with better antidepressant response to chronic citalopram treatment. These data are consistent with previous studies of total sleep deprivation and suggest that dynamic, early adaptive changes or normalization of cerebral metabolism may represent early neurobiological markers of chronic SSRI treatment response in geriatric depression.",
keywords = "antidepressant, biomarker, citalopram, Depression, geriatric, glucose metabolism, PET, treatment response",
author = "Gwenn Smith and Workman, {Clifford I.} and Elisse Kramer and Hermann, {Carol R.} and Rachel Ginsberg and Yilong Ma and Vijay Dhawan and Thomas Chaly and David Eidelberg",
year = "2011",
month = "1",
doi = "10.1097/JGP.0b013e3181eafde4",
language = "English (US)",
volume = "19",
pages = "53--63",
journal = "American Journal of Geriatric Psychiatry",
issn = "1064-7481",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - The relationship between the acute cerebral metabolic response to citalopram and chronic citalopram treatment outcome

AU - Smith, Gwenn

AU - Workman, Clifford I.

AU - Kramer, Elisse

AU - Hermann, Carol R.

AU - Ginsberg, Rachel

AU - Ma, Yilong

AU - Dhawan, Vijay

AU - Chaly, Thomas

AU - Eidelberg, David

PY - 2011/1

Y1 - 2011/1

N2 - Objectives: Given the challenges in the clinical management of geriatric depression, research over the past decade has focused on developing early neurobiological markers of antidepressant treatment response. This study tested the hypothesis that lower baseline glucose metabolism and greater acute cerebral metabolic responses to a single, intravenous (IV) dose of the selective serotonin reuptake inhibitor (SSRI) citalopram would be associated with greater improvement of depressive symptoms after 12 weeks of citalopram treatment in geriatric depression. Methods: Sixteen geriatric depressed patients underwent two scans to measure cerebral glucose metabolism after administration of either a saline placebo or citalopram infusion (40 mg, IV). Then, the patients were treated with the oral citalopram medication for 12 weeks. Results: Greater improvement of depressive symptoms was associated with lower baseline metabolism in anterior cingulate, superior, middle, and inferior frontal gyri (bilaterally), inferior parietal lobule (bilaterally), precuneus (right), insula (left), parahippocampal gyrus (right), caudate (bilaterally), and putamen (left) regions. Greater improvement of depressive symptoms was associated with greater reductions in metabolism after acute citalopram administration in similar brain regions, including additional posterior cortical regions. Conclusions: Lower baseline cerebral metabolism and greater decreases with acute citalopram administration are associated with better antidepressant response to chronic citalopram treatment. These data are consistent with previous studies of total sleep deprivation and suggest that dynamic, early adaptive changes or normalization of cerebral metabolism may represent early neurobiological markers of chronic SSRI treatment response in geriatric depression.

AB - Objectives: Given the challenges in the clinical management of geriatric depression, research over the past decade has focused on developing early neurobiological markers of antidepressant treatment response. This study tested the hypothesis that lower baseline glucose metabolism and greater acute cerebral metabolic responses to a single, intravenous (IV) dose of the selective serotonin reuptake inhibitor (SSRI) citalopram would be associated with greater improvement of depressive symptoms after 12 weeks of citalopram treatment in geriatric depression. Methods: Sixteen geriatric depressed patients underwent two scans to measure cerebral glucose metabolism after administration of either a saline placebo or citalopram infusion (40 mg, IV). Then, the patients were treated with the oral citalopram medication for 12 weeks. Results: Greater improvement of depressive symptoms was associated with lower baseline metabolism in anterior cingulate, superior, middle, and inferior frontal gyri (bilaterally), inferior parietal lobule (bilaterally), precuneus (right), insula (left), parahippocampal gyrus (right), caudate (bilaterally), and putamen (left) regions. Greater improvement of depressive symptoms was associated with greater reductions in metabolism after acute citalopram administration in similar brain regions, including additional posterior cortical regions. Conclusions: Lower baseline cerebral metabolism and greater decreases with acute citalopram administration are associated with better antidepressant response to chronic citalopram treatment. These data are consistent with previous studies of total sleep deprivation and suggest that dynamic, early adaptive changes or normalization of cerebral metabolism may represent early neurobiological markers of chronic SSRI treatment response in geriatric depression.

KW - antidepressant

KW - biomarker

KW - citalopram

KW - Depression

KW - geriatric

KW - glucose metabolism

KW - PET

KW - treatment response

UR - http://www.scopus.com/inward/record.url?scp=78650781693&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650781693&partnerID=8YFLogxK

U2 - 10.1097/JGP.0b013e3181eafde4

DO - 10.1097/JGP.0b013e3181eafde4

M3 - Article

VL - 19

SP - 53

EP - 63

JO - American Journal of Geriatric Psychiatry

JF - American Journal of Geriatric Psychiatry

SN - 1064-7481

IS - 1

ER -